A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

NCT06384352 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: YL211

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Collaborators

[object Object]